PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel’s take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.

Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Go online to PeerView.com/TFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in the management of venous thromboembolism (VTE) discuss the importance of a timely diagnosis, appropriate treatment selection, and extended anticoagulation therapy for secondary prevention. Upon completion of this activity, participants should be better able to: Apply appropriate evidence-based clinical decision tools in an interprofessional manner to identify patients in primary care at risk for VTE, Compare the efficacy and safety profile and dosing regimens of available treatment options for VTE, Implement the most up-to-date evidence-based guidelines in the management of VTE to determine an individually appropriate treatment strategy for each patient, Explain the indications and rationale for standard vs extended treatment for the secondary prevention of VTE, Educate patients on the heightened risk of VTE recurrence, and the importance of treatment adherence.

Go online to PeerView.com/TRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to bring the new standard of care for advanced renal cell carcinoma (RCC) into your clinical practice? Join PeerView and KCCure to learn what the latest research on multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) means for your patients with advanced disease. Our panel of experts will discuss how highly efficacious therapeutic strategies are changing outcomes in earlier lines of treatment and the potential for approved agents to be used in new settings. With illustrative patient cases guiding the discussion, this engaging activity will provide participants with the information they need to navigate important clinical decisions, including how to sequence available therapies; which systemic therapies to use in patients with metastatic, locally advanced, or high-risk localized disease; what steps should be taken to manage AEs associated with newer treatment strategies; and which patients could benefit from clinical trial enrollment. Don’t miss this opportunity to learn more about providing guideline-recommended individualized care for your patients with RCC. Upon completion of this CE activity, participants will be able to: Incorporate novel therapeutic approaches, latest clinical evidence, expert recommendations, and patient-, disease-, and treatment-specific factors in the development of contemporary, personalized management plans for patients with RCC, Recommend clinical trials evaluating novel agents and/or combination approaches as standard treatment options for eligible patients with RCC across the disease spectrum, Apply evidence-based strategies and best practices to diagnose, mitigate, and manage AEs related to novel systemic therapies, including combination regimens, for patients with RCC.

Go online to PeerView.com/DQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in acute hepatic porphyria (AHP) reviews the diagnostic criteria for AHP and examines current treatment options. Upon completion of this activity, participants should be better able to: Apply laboratory and diagnostic assessments to confirm suspicion of AHP, Recognize disease burdens that patients with AHP frequently experience (eg, impact on overall health, quality of life, daily activities), Employ evidence-based treatment regimens that include siRNA therapy, as appropriate, to improve outcomes, minimize disease impact, and reduce the burdens of disease in patients with AHP.

Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to include expanded and detailed recommendations for the use of dual antiplatelet therapy (DAPT), the combination of aspirin and clopidogrel or ticagrelor, to further reduce the risk of stroke. These guidelines also include specific recommendations for individuals with minor acute ischemic stroke (AIS) or a TIA. In this activity based on a recent satellite symposium in New Orleans, leading experts on stroke management highlight the current guideline recommendations and discuss the latest perspectives on DAPT before transitioning to patient case scenarios where each expert demonstrates how these advances can be translated into clinical practice to improve outcomes and reduce the risk of recurrent stroke, while accounting for bleeding risks, antiplatelet resistance, and patient adherence. Upon completion of this CE activity, participants will be able to: Identify individuals with AIS or TIA who are appropriate candidates for treatment with antiplatelet therapy to reduce the risk of recurrent stroke, Assess the benefits and risks of using P2Y12 inhibitors with aspirin as DAPT for the prevention of recurrent stroke, Apply DAPT with P2Y12 inhibitors in appropriate patients following symptom onset to reduce the risk of recurrent stroke, Employ patient-centered communication strategies to facilitate adherence to DAPT with P2Y12 inhibitors in appropriate patients with AIS or TIA to reduce the risk of recurrent stroke.

Go online to PeerView.com/FFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the life-changing impact of gene replacement therapy in spinal muscular atrophy. Upon completion of this CE activity, participants will be able to: Recognize the underlying genetics and pathophysiology of spinal muscular atrophy, Identify appropriate patients with SMA for treatment with gene replacement therapy, Counsel patients, families, and caregivers about gene replacement therapy for SMA, including eligibility, potential benefits and risks, and anticipatory guidance regarding prognosis, the need for ongoing care, and long-term safety monitoring, Employ post-treatment multidisciplinary management plans for patients who have been treated for SMA with gene replacement therapy.